Abstract
To overcone hemorrhage complications during extracorporeal circulatory support, we introduced the newly developed heparin-coated PCPS (CPS-HP, Terunro Inc.) and evaluated its efficacy. The CPS-HP was tested in 10 patients (postcardiotony shock in 5 patients, AMI in 3, and acute fluminant nyocarditis in 2). During the support, low dose heparin was adninistered continuously to maintain ACT around 150 sec. Four patients (40%) were weaned fromPCPS, and 3 patients (30%) are long termsurvivors. Two cases were weaned after over 200 hours support without exchanging the CPS-HP system Although administered heparin dose was 156±84U/hour, there was no thromboembolic nor hemorrhagic complications during the support in all cases. In previous heparin coated PCPS system (Carnnda Bioactive Surface®) in our hospital, 4 of 24 cases caused plasma leakage of the oxygenator. But there was no plasixa leakage in CPS-HP oxygenator. And also life tine of the CPS-HP oxygenator was significantly longer than that of the Carmeda coating system (CPS-HP; 98±93 vs. Carmeda; 14±13 hours, p<0.05). In conclusion, these result suggest the good durability and efficacy of the CPS-HP for long term temporary support.
